Modern drug discovery relies on two key capabilities: 1) high-throughput experimental screening of large, diverse chemical or biological libraries, and 2) a detailed understanding of molecular interactions to enable rational design and optimization. However, these two needs are often seen as a trade-off in early discovery, with campaigns typically emphasizing speed and broad coverage in primary screening, deferring mechanistic and selectivity characterization until later, when time, material requirements, and downstream risks increase. To bridge this gap, there is a growing need for platforms that combine screening-scale throughput with high-quality characterization.
To download the rest of the application note, please fill out the short form below. Thank you.